Topoisomerase II InhibitorsEtoposideDNA Topoisomerases, Type IIAmsacrineTeniposideTopoisomerase I InhibitorsEllipticinesDNA Topoisomerases, Type IRazoxaneTopoisomerase InhibitorsPodophyllotoxinNovobiocinThiobarbituratesAntineoplastic Agents, PhytogenicIntercalating AgentsEnzyme InhibitorsCamptothecinDNA DamageDoxorubicinAntineoplastic AgentsAclarubicinAminoacridinesMitoxantroneDNANucleic Acid Synthesis InhibitorsTumor Cells, CulturedAntigens, NeoplasmMyeloid-Lymphoid Leukemia ProteinDNA-Binding ProteinsAntibiotics, AntineoplasticDrug Screening Assays, AntitumorDrug ResistanceDNA Topoisomerase IVDNA, SuperhelicalLeukemia P388TopotecanDNA, NeoplasmCell CycleCell SurvivalApoptosisDrug Resistance, NeoplasmCricetinaeNeoplasms, Second PrimaryDaunorubicinKB CellsG2 PhasePiperazinesLeukemia, Radiation-InducedCell LineCricetulusBase SequenceCisplatinDNA, CatenatedMitosisCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsHeterocyclic Compounds with 4 or More RingsMolecular Sequence DataHL-60 CellsDNA CleavageLeukemia, MyeloidAnthraquinonesLeukemiaTranslocation, GeneticDNA RepairChromosomes, Human, Pair 11HeLa CellsDNA TopoisomerasesDose-Response Relationship, DrugProto-OncogenesCarcinoma, Small CellDNA, KinetoplastIsoenzymesDrug InteractionsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesCell DivisionLeukemia L1210Tumor Suppressor Protein p53Chromosome AberrationsNeoplasmsCrithidia fasciculataCell NucleusTime FactorsDNA ReplicationKineticsQuinolonesIfosfamideNucleic Acid ConformationLung NeoplasmsMutationTranscription FactorsChromosomesDNA GyraseCatalysisVincristineSaccharomyces cerevisiaeNaphthalimidesPlasmids